Loading...

NLVX

NLV

ENLIVEX LTD

(ENLV)

2025 6-K

Nasdaq Notice Received

15 May '26

Clinical Trial Approval

21 Apr '26

Token Launch Announced

8 Apr '26

New AI Initiative

26 Mar '26

Financial Results Release

25 Mar '26

Securities Agreement

24 Mar '26

FDA Approval Granted

23 Mar '26

Name Change Approved

23 Feb '26

RAIN Token Listing

10 Feb '26

Shareholder Meeting

5 Feb '26

RAIN Token Listing

26 Jan '26

Voluntary Delisting

23 Jan '26

New Token Listing

7 Jan '26

Shareholder Meeting Announc...

18 Dec '25

Virtual Fireside Chat

4 Dec '25

Private Placement Completed

26 Nov '25

Annual Meeting Update

18 Nov '25

Financial Results Report

14 Nov '25

Annual Meeting Update

10 Nov '25

Annual Meeting Scheduled

25 Sep '25

Strategic Roadmap Update

11 Sep '25

Patent Announcement

9 Sep '25

Financial Update

29 Aug '25

Investor Presentation Update

18 Aug '25

Clinical Trial Update

18 Aug '25

Webinar Announcement

14 Aug '25

Trial Completion Announcement

28 Jul '25

Financial Report

30 May '25

Presentation Announcement

23 Apr '25

Trial Enrollment Complete

21 Apr '25

Trial Announcement

3 Apr '25

Financial Statements Filed

31 Mar '25

Patent Approval News

17 Mar '25

Investor Webinar Notice

4 Mar '25

Positive Trial Results

3 Mar '25

Fraudulent News Alert

18 Feb '25

Clinical Trial Initiation

11 Dec '24

Positive Trial Results

3 Dec '24

Financial Update

29 Nov '24

Bitcoin Acquisition

20 Nov '24

Clinical Trial Update

14 Nov '24

Patient Enrollment Update

12 Nov '24

Annual Meeting Results

8 Nov '24

Annual Meeting Update

31 Oct '24

Patent Approval Update

30 Oct '24

Filing Amendment

15 Oct '24

Phase II Trial Approval

26 Sep '24

Clinical Trial Update

24 Sep '24

Annual Meeting Notice

11 Sep '24

Financial Update

30 Aug '24

Clinical Trial Approval

23 Jul '24

Trial Initiated

24 Jun '24

Investor Webinar Notice

20 Jun '24

Positive Clinical Data

17 Jun '24

Financial Report

14 Jun '24

Regulatory Approval

3 Jun '24

Securities Offering

29 May '24

Share Issuance Agreement

28 May '24

Shareholder Update

29 Apr '24

Trial Announcement

22 Apr '24

Trial Expansion Approval

16 Apr '24

Clinical Trial Results

11 Apr '24

Financial Statements Report

29 Mar '24

New Patent Granted

7 Feb '24

Share Repurchase Program

22 Jan '24

Trial Authorization

17 Jan '24

External Links:

SEC

On April 21, 2025, Enlivex Therapeutics Ltd. announced the completion of patient enrollment for its Phase II trial focused on Allocetra™ for knee osteoarthritis. This is a significant event as it advances their clinical research efforts.

AI Assistant

ENLIVEX LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.